Reply to Parra-Ruiz

Clinical Infectious Diseases

Volumn 57, Issue 8, 2013, Pages 1219-1220

  Van Hal, Sebastiaan J ^a,b   Fowler Jr , Vance G ^c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ANTIMICROBIAL THERAPY; BACTERIUM ISOLATE; CRITICALLY ILL PATIENT; DRUG COST; HUMAN; KIDNEY INJURY; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84884960138     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit460     Document Type: Letter

References (12)

1. Parra-Ruiz J
2. van Hal SJ, Fowler VG Jr. Is it time to replace vancomycin in the treatment of methicillinresistant Staphylococcus aureus infections? Clin Infect Dis 2013; 56:1779-88.
3. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621-9.
4. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a casecontrol study. Clin Infect Dis 2012; 54:51-8.
5. Murray KP, Zhao JJ, Davis SL, et al. Early use of daptomycin versus vancomycin for methicillin- resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis 2013; 56:1562-9.
6. Weston A, Boucher HW. Daptomycin for methicillin-resistant Staphylococcus aureus bloodstream infection and elevated vancomycin minimum inhibitory concentrations: has the time come? Clin Infect Dis 2012; 54:59-61.
7. Weston A, Boucher HW. Early high-dose daptomycin for methicillin- resistant Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentrations: ready for prime time? Clin Infect Dis 2013; 56:1570-2.
8. Fowler VG Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
9. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycininduced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013; 57:734-44.
10. Baos E, Candel FJ, Merino P, Pena I, Picazo JJ. Characterization and monitoring of linezolid- resistant clinical isolates of Staphylococcus epidermidis in an intensive care unit 4 years after an outbreak of infection by cfrmediated linezolid-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2013; 76:325-9.
11. Bounthavong M, Hsu DI. Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections. Expert Rev Pharmacoecon Outcomes Res 2012; 12:683-98.
12. Bounthavong M, Zargarzadeh A, Hsu DI, Vanness DJ. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health 2011; 14: 631-9.